| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
92.46(B) |
| Last
Volume: |
505,652 |
Avg
Vol: |
771,513 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
41,535 |
84,942 |
120,451 |
283,828 |
| Total Sell Value |
$39,627,604 |
$77,255,398 |
$106,928,922 |
$220,981,114 |
| Total People Sold |
9 |
13 |
15 |
17 |
| Total Sell Transactions |
21 |
38 |
54 |
116 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2024-01-02 |
4 |
AS |
$900.00 |
$15,163,200 |
I/I |
(16,848) |
180,000 |
|
-2% |
|
| Coles N Anthony |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
1,393 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
18,482 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2024-01-02 |
4 |
AS |
$873.91 |
$89,990 |
D/D |
(100) |
18,347 |
|
-2% |
|
| Poon Christine A |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
135 |
2,172 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-28 |
4 |
D |
$884.88 |
$541,547 |
D/D |
(612) |
21,807 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-28 |
4 |
OE |
$378.98 |
$322,133 |
D/D |
850 |
22,419 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-27 |
4 |
D |
$872.21 |
$472,738 |
D/D |
(542) |
21,569 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-27 |
4 |
OE |
$378.98 |
$284,235 |
D/D |
750 |
22,111 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2023-12-27 |
4 |
AS |
$898.00 |
$1,840,002 |
D/D |
(2,049) |
1,247 |
|
1% |
|
| Brown Michael S |
Director |
– • – |
2023-12-27 |
4 |
OE |
$482.68 |
$989,011 |
D/D |
2,049 |
3,296 |
|
- |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2023-12-27 |
4 |
AS |
$856.71 |
$2,097,226 |
D/D |
(2,448) |
14,372 |
|
1% |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2023-12-22 |
4 |
AS |
$846.27 |
$211,568 |
D/D |
(250) |
16,820 |
|
4% |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2023-12-21 |
4 |
AS |
$843.79 |
$1,417,934 |
D/D |
(1,680) |
17,070 |
|
5% |
|
| Bassler Bonnie L |
Director |
– • – |
2023-12-13 |
4 |
AS |
$870.00 |
$530,700 |
D/D |
(610) |
1,247 |
|
2% |
|
| Bassler Bonnie L |
Director |
– • – |
2023-12-13 |
4 |
OE |
$376.69 |
$229,781 |
D/D |
610 |
1,857 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-13 |
4 |
D |
$871.12 |
$629,820 |
D/D |
(723) |
21,361 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-13 |
4 |
OE |
$378.98 |
$378,980 |
D/D |
1,000 |
22,084 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-12-12 |
4 |
D |
$856.71 |
$6,559,828 |
D/D |
(7,657) |
48,306 |
|
- |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2023-12-12 |
4 |
D |
$856.71 |
$2,186,324 |
D/D |
(2,552) |
18,750 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-12-12 |
4 |
D |
$856.71 |
$4,373,505 |
D/D |
(5,105) |
15,336 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-12 |
4 |
D |
$856.71 |
$5,466,667 |
D/D |
(6,381) |
21,084 |
|
- |
|
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO |
• • – |
2023-12-11 |
4 |
D |
$844.09 |
$10,838,960 |
D/D |
(12,841) |
374,429 |
|
- |
|
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO |
• • – |
2023-12-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,155 |
387,270 |
|
- |
|
| Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2023-12-11 |
4 |
D |
$844.09 |
$10,838,960 |
D/D |
(12,841) |
752,486 |
|
- |
|
1366 Records found
|
|
Page 4 of 55 |
|
|
7.48 (0.84%) 
